Rodent idiopathic pulmonary fibrosis (IPF) model

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal interstitial lung disease characterized by excessive extracellular matrix deposition, alveolar destruction, and loss of lung function. HKeyBio offers three well-validated rodent IPF models: (1) BLM-induced SD rat model, which is the most widely used model in IPF research and is induced by intratracheal instillation of bleomycin; (2) SiO2-induced C57BL/6 mouse model, which represents occupational silica-induced pulmonary fibrosis; (3) SiOx-induced SD rat model, which is a model of chronic fibrotic lung disease caused by crystalline silica exposure. These models recapitulate key features of human IPF, including weight loss, inflammatory cell infiltration in BALF, decreased lung function, and progressive fibrotic pathology (Masson's trichrome, HE, PSR staining). They provide a powerful platform for preclinical efficacy testing of novel antifibrotic therapies.

Quantity:
Availability:





Inquire Add to Basket

Product Description

Main features and benefits

Multiple etiological – chemical (BLM) and occupational (silica) induced models cover different pathogenic mechanisms of IPF.

Comprehensive endpoint - body weight, BALF cytology (inflammatory cells), lung function, histopathology (HE, Masson, PSR), pathology score.

Translational Value – Ideal for testing antifibrotic drugs (nintedanib, pirfenidone), TGF-β inhibitors, and novel therapeutic candidates.

Species options – Rat and mouse models are available to meet different experimental requirements.

IND Ready Packet – Research can be conducted in accordance with GLP principles.

Technical data and verification

Representative data from our NHP atopic dermatitis (AD) model:

BLM induction C57BL/6 IPF model

SiO ₂ -induced C57BL/6 IPF model

SiO ₂ induced rat IPF model

Application areas

• Efficacy testing of antifibrotic drugs (nintedanib, pirfenidone, TGF-β inhibitors, lysyl oxidase inhibitors)

• Target validation of fibrotic pathways (TGF-β, CTGF, PDGF)

• Biomarker discovery (collagen deposition markers, inflammatory mediators)

• Mechanism of action (MOA) studies

• Pharmacology and toxicology studies to support IND

Model specifications

scope	BLM induces IPF in rats	SiO2 induces IPF in mice	SiOx-induced IPF in rats
Species/Strain	Sprague-Dawley Rat	C57BL/6 mouse	Sprague-Dawley Rat
induction method	Intratracheal bleomycin (single dose)	Intratracheal SiO2 (single dose)	Intratracheal crystalline silica (SiOx)
study time	14–28 days	45 days	28–56 days
critical endpoint	Body weight, BALF cytology (total number of cells, classification), lung function, histopathology (HE, Masson), pathology score	Weight, lung function, pathology score, histopathology (HE, Masson, PSR)	Body weight, BALF neutrophils, histopathology (HE, Masson, PSR)
packet	Raw data, analysis report, BALF cytology, histology sections (HE, Masson, PSR), lung function data, bioinformatics (optional)

❓ FAQ

Q: What is the difference between BLM and silica-induced IPF models?

A: BLM induces acute lung injury followed by fibrosis, similar to drug-induced IPF. Silica models (SiO2, SiOx) represent occupational/environmental exposures, slower progression and chronic inflammation, and better reflect human silicosis and some forms of IPF.

Q: Which model is best for testing anti-fibrotic drugs?

A: The BLM rat model is the most widely accepted for antifibrotic drug screening due to its rapid onset of action and good reproducibility. The silica model is the first choice for studying interventions in chronic fibrosis and occupational lung disease.

Q: Can these models be used for IND support studies?

Answer: Yes. Studies can be conducted according to GLP principles for regulatory submissions (FDA, EMA).

Q: Do you offer customized study protocols (e.g., different doses, time points, combination therapies)?

Answer: Of course. Our scientific team tailors induction protocols, treatment plans and endpoint analyzes for your specific drug candidate.